National

Finish Line

Axios Finish Line

Behind the Curtain: China wins by watching

Macro

Axios Macro

Rumors of the dollar's demise look much exaggerated

Americans grow a bit friendlier toward China

A line chart that shows Americansâ favorable views of China from 2020 to 2026. Favorability was 19% in 2020, rose to 21% in 2021, fell to a low of 14% in 2023, then climbed to 27% in 2026, the series high.

Favorability of China among Americans over time

Health Care Policy

Pharma tariffs force biotech to weigh price deals

U.S. warships cross Strait of Hormuz for first time since Iran war began

Media Trends

Axios Media Trends

America's loudest export is cranking the volume

Media Trends Executive

It's Trump's trade world now

A line chart that tracks the average effective tariff rate daily from Jan. 1, 2025, to April 2, 2026. The rate rises from 2.3% to a peak of 21% on April 11, 2025, then eases to 11% by Feb. 20, 2026 after the Supreme Court strikes down tariffs implemented under the International Emergency Economic Powers Act, where it remains through April 2, 2026.

Average effective tariff rate

Data: Yale Budget Lab; Chart: Erin Davis/Axios Visuals

China and Pakistan present new Iran deal: Ceasefire for opening Hormuz

China's rise threatens the drug world's status quo

Exclusive: U.S. and China could agree on AI guidelines, says Hicks

Back to World

The developments that matter out of Beijing.

China

China coverage from Axios

Israel

Ukraine

Iran

Russia

Conflicts, policies and powers are intersecting and shaping the world. Breaking news and analysis of national security, foreign policy and global crises.

World

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

c-suite

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

boulder

detroit

kansas-city

columbus

austin

dallas

atlanta

washington-dc

nw-arkansas

chicago

indianapolis

nashville

richmond

colorado-springs

houston

san-francisco

seattle

boston

des-moines

salt-lake-city

philadelphia

denver

phoenix

new-orleans

miami

twin-cities

raleigh

san-antonio

portland

san-diego

tampa-bay

cleveland

huntsville

pittsburgh

axios-local

axios-pro

axios-live

the-axios-show